The National Institute for Health and Care Excellence (NICE) has approved teplizumab for use on the NHS in England and Wales, making it available to patients to delay the onset of type 1 diabetes. Multiple outlets describe teplizumab as the first treatment that slows or postpones the early development of the disease. The drug is reported to delay progression to type 1 diabetes by up to three years, for people who are at risk of developing the condition.
Coverage highlights that type 1 diabetes typically develops in childhood or adolescence and is caused by the immune system damaging the pancreas, resulting in little or no insulin production. By targeting the disease process before full onset, teplizumab is presented as a potential shift in how early-stage risk is managed, rather than treating established diabetes.
Diabetes UK and other commentators characterize the decision as a major breakthrough, with reporting framing it as “a new age” of treatment and the biggest advance in tackling type 1 diabetes in more than a century. The outlets agree on the approval and the reported potential to postpone onset by up to three years.
